Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy PhaseBio Pharmaceuticals stock | $3.77

Learn how to easily invest in PhaseBio Pharmaceuticals stock.

PhaseBio Pharmaceuticals Inc is a biotechnology business based in the US. PhaseBio Pharmaceuticals shares (PHAS) are listed on the NASDAQ and all prices are listed in US Dollars. PhaseBio Pharmaceuticals employs 55 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in PhaseBio Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PHAS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

PhaseBio Pharmaceuticals stock price (NASDAQ: PHAS)

Use our graph to track the performance of PHAS stocks over time.

PhaseBio Pharmaceuticals shares at a glance

Information last updated 2021-10-23.
Latest market close$3.77
52-week range$2.60 - $5.83
50-day moving average $3.31
200-day moving average $3.37
Wall St. target price$16.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.23

Buy PhaseBio Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Webull
Stocks, Options, ETFs
$0
0%
Get two free stocks valued between $3.00 and $300 with a deposit to any new account.
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy PhaseBio Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

PhaseBio Pharmaceuticals price performance over time

Historical closes compared with the close of $3.77 from 2021-10-27

1 week (2021-10-21) -5.04%
1 month (2021-09-28) 22.40%
3 months (2021-07-28) 5.90%
6 months (2021-04-28) 20.83%
1 year (2020-10-28) 37.59%
2 years (2019-10-28) -7.82%
3 years (2018-10-26) 5
5 years (2016-10-24) N/A

PhaseBio Pharmaceuticals financials

Revenue TTM $10.3 million
Gross profit TTM $-71,768,000
Return on assets TTM -67.93%
Return on equity TTM -3091.02%
Profit margin 0%
Book value $0.18
Market capitalisation $192.2 million

TTM: trailing 12 months

Shorting PhaseBio Pharmaceuticals shares

There are currently 2.1 million PhaseBio Pharmaceuticals shares held short by investors – that's known as PhaseBio Pharmaceuticals's "short interest". This figure is 12.3% down from 2.4 million last month.

There are a few different ways that this level of interest in shorting PhaseBio Pharmaceuticals shares can be evaluated.

PhaseBio Pharmaceuticals's "short interest ratio" (SIR)

PhaseBio Pharmaceuticals's "short interest ratio" (SIR) is the quantity of PhaseBio Pharmaceuticals shares currently shorted divided by the average quantity of PhaseBio Pharmaceuticals shares traded daily (recently around 335545.41139241). PhaseBio Pharmaceuticals's SIR currently stands at 6.32. In other words for every 100,000 PhaseBio Pharmaceuticals shares traded daily on the market, roughly 6320 shares are currently held short.

However PhaseBio Pharmaceuticals's short interest can also be evaluated against the total number of PhaseBio Pharmaceuticals shares, or, against the total number of tradable PhaseBio Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PhaseBio Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 PhaseBio Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0548% of the tradable shares (for every 100,000 tradable PhaseBio Pharmaceuticals shares, roughly 55 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against PhaseBio Pharmaceuticals.

Find out more about how you can short PhaseBio Pharmaceuticals stock.

PhaseBio Pharmaceuticals share dividends

We're not expecting PhaseBio Pharmaceuticals to pay a dividend over the next 12 months.

PhaseBio Pharmaceuticals share price volatility

Over the last 12 months, PhaseBio Pharmaceuticals's shares have ranged in value from as little as $2.6 up to $5.83. A popular way to gauge a stock's volatility is its "beta".

PHAS.US volatility(beta: 1.59)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PhaseBio Pharmaceuticals's is 1.5936. This would suggest that PhaseBio Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

PhaseBio Pharmaceuticals overview

PhaseBio Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc.

Frequently asked questions

What percentage of PhaseBio Pharmaceuticals is owned by insiders or institutions?
Currently 6.889% of PhaseBio Pharmaceuticals shares are held by insiders and 77.247% by institutions.
How many people work for PhaseBio Pharmaceuticals?
Latest data suggests 55 work at PhaseBio Pharmaceuticals.
When does the fiscal year end for PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals's fiscal year ends in December.
Where is PhaseBio Pharmaceuticals based?
PhaseBio Pharmaceuticals's address is: 1 Great Valley Parkway, Malvern, PA, United States, 19355
What is PhaseBio Pharmaceuticals's ISIN number?
PhaseBio Pharmaceuticals's international securities identification number is: US7172241090
What is PhaseBio Pharmaceuticals's CUSIP number?
PhaseBio Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 717224109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site